Clinical trials: Neurocognitive Disorders, Mild
Alzheimer Disease
Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
The purpose of this study is to assess the long term safety, tolerability, and immunogenicity of ACC-001, an investigational active immunization product+, in subjects with mild to moderate Alzheimer's disease.
- Trial name
- NCT00955409
- Testing
- ACC-001(3µg) + QS21, ACC-001(10µg) + QS21, ACC-001(30µg) + QS21
- Where
- 17 sites in France, Germany and 1 more
- Volunteers
- 160 people
- Sponsor
- Pfizer
Alzheimer's Disease
Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil
To establish efficacy of Idalopirdine as adjunctive therapy to donepezil for symptomatic treatment of patients with mild-to-moderate Alzheimer's disease (AD).
- Trial name
- STARBEAM (NCT02006641)
- Testing
- Idalopirdine
- Where
- 162 sites in United States, Argentina and 17 more
- Volunteers
- 858 people
- Sponsor
- H. Lundbeck A/S
Coronary Artery Disease, Mild Cognitive Impairment
Genomic Outcomes of Metformin
Medical scientists have found that people with diabetes who take the drug Metformin have less age-related disease than those taking other treatments and researchers believe it may prevent numerous diseases and conditions that…
- Conditions
- Coronary Artery Disease, Mild Cognitive Impairment, Obesity, Abdominal, Hypertension
- Trial name
- GOMET (NCT02986659)
- Testing
- Metformin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Wake Forest University Health Sciences
Mild Cognitive Impairment, Cognitive Change
Conversations as a Means to Delay the Onset of Alzheimer's Disease
Past epidemiological studies have demonstrated that larger social networks, or more frequent social interactions, could have potential protective effects on the incidence of Alzheimer's Disease (AD).
- Trial name
- conversation (NCT01571427)
- Testing
- Active social engagement group, Control group
- Where
- United States
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Mild Cognitive Impairment, Alzheimer Disease
Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease
The purpose of this platform study was to evaluate the effect of anti-inflammatory agents on cognition in early Alzheimer's disease.
- Trial name
- NCT04795466
- Testing
- Canakinumab
- Where
- 10 sites in United States, Finland and 2 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Dementia Prevention, Mild Cognitive Impairment
Brain Health Support Program
The Canadian Therapeutic Platform Trial for Multidomain Interventions to Prevent Dementia (CAN-THUMBS UP, or CTU) is a comprehensive and innovative program aimed to develop, implement and evaluate an interactive and compelling…
- Conditions
- Dementia Prevention, Mild Cognitive Impairment, Subjective Cognitive Impairment, Cognitive Change
- Trial name
- CTU: BHSP (NCT05347966)
- Testing
- Brain Health PRO
- Where
- 7 sites in Canada
- Volunteers
- 354 people
- Sponsor
- Baycrest
Alzheimer's Disease
Computerized Cognition Testing in Participants With Mild Alzheimer's Disease (AD) Treated With Donepezil (MK-0000-318)
This study aims to determine whether the Cogstate testing battery can detect improvements in cognitive function in participants with mild AD.
- Trial name
- NCT02064920
- Testing
- Donepezil
- Volunteers
- 36 people
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer's Disease
Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease
The primary purpose of this study is to assess the safety and tolerability of TRx0237 when taken at the same time as acetylcholinesterase inhibitors (i.e., donepezil, galantamine, or rivastigmine) and / or memantine to treat…
- Trial name
- NCT01626391
- Testing
- TRx0237
- Where
- 12 sites in Germany, United Kingdom
- Volunteers
- 9 people
- Sponsor
- TauRx Therapeutics Ltd
Mild Cognitive Impairment
Feasibility of Gamma Transcranial Alternating Current Stimulation to Reduce Beta-amyloid Load and Improve Memory
This project assessed the feasibility of transcranial alternating current stimulation in the gamma band to lower beta-amyloid load and improve memory performance.
- Trial name
- NCT04646499
- Testing
- Transcranial alternating current stimulation
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Mild Cognitive Impairment, Insomnia
Multicomponent Behavioral Sleep Intervention for Insomnia in Older Adults With Mild Cognitive Impairment
Insomnia symptoms in older adults with mild cognitive impairment represent a significant public health burden in terms of impaired quality of life, risks from untreated insomnia, and risks from pharmaceutical insomnia treatment.
- Trial name
- MBSI-I (NCT04364191)
- Testing
- Multicomponent Behavioral Sleep Intervention for Insomnia, Active Control
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Alzheimer's Disease, Oxidative Stress
Fish Oil and Alpha Lipoic Acid in Treating Alzheimer's Disease
The purpose of this study is to determine the effect of fish oil and the antioxidant alpha lipoic acid on factors in the blood that are associated with the progression of Alzheimer's Disease (AD).
- Conditions
- Alzheimer's Disease, Oxidative Stress, Dementia, Hyperlipidemia
- Trial name
- NCT00090402
- Testing
- Fish Oil, Lipoic Acid
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Oregon Health and Science University
Healthy Volunteers
A Study of LY2886721 in Healthy Participants
The purpose of this phase I study in healthy participants will be to evaluate the safety and tolerability of LY2886721 single and multiple doses, to evaluate how the body handles the drug, and to evaluate the drug's effect on the…
- Trial name
- NCT01534273
- Testing
- LY2886721
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Mild Cognitive Impairment
SYNchronizing Exercises, Remedies in GaIt and Cognition
The proposed SYNERGIC trial is uniquely designed to evaluate the effect of aerobic and progressive resistance training exercises, combined with cognitive training and Vitamin D3 supplementation, in cognition and mobility in older…
- Trial name
- SYNERGIC (NCT02808676)
- Testing
- Vitamin D3, Exercises (E), Cognitive Training (CT)
- Where
- 6 sites in Canada
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Mild Alzheimer's Disease
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease
The purpose of this study was to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS-MAPTRx in patients with Mild Alzheimer's Disease.
- Trial name
- NCT03186989
- Testing
- IONIS MAPTRx
- Where
- 13 sites in Canada, Finland and 4 more
- Volunteers
- 46 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Mild Cognitive Impairment
Cognitive Training and Practice Effects in Mild Cognitive Impairment
The current study will test the effectiveness of a computerized cognitive training program on auditory memory and attention in patients with mild cognitive impairment.
- Trial name
- NCT02301546
- Testing
- computerized cognitive exercises
- Where
- United States
- Volunteers
- 197 people
- Sponsor
- University of Utah
Mild Cognitive Impairment
Home-Based Dual-Task Training for Older Adults
This project is focused on conducting a home-based, thinking while moving exercise intervention for adults 65 years or older, who have mild cognitive impairment, that will integrate several effective training modalities including…
- Trial name
- NCT05108246
- Testing
- Dual-Task Exercise Training
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- State University of New York at Buffalo
Cognitive Decline, Dementia
Effects of Strengthening Exercise on the Brain for Early Dementia and Normative Older Adults
This study will evaluate the effects of low-intensity strengthening exercise on the brain (thinking and processing speed) for patients with early dementia, compared with normative older adults.
- Conditions
- Cognitive Decline, Dementia, Alzheimer's Disease, Mild Cognitive Impairment
- Trial name
- NCT01264614
- Testing
- Strengthening exercise
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Union College, New York
Alzheimer Disease, Dementia
Semantic Memory, Financial Capacity, and Brain Perfusion in Mild Cognitive Impairment (MCI) (CASL)
Alzheimer's disease (AD) often manifests as a memory disorder before dementia develops. Dementia is considered to be present when a person can no longer handle complex activities of daily living, such as managing finances.
- Trial name
- CASL (NCT00880555)
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Alzheimer's Disease
Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD
This study will assess the effects of VX-745 on markers of disease in the central nervous system of patients with MCI due to AD or with mild AD.
- Trial name
- NCT02423200
- Testing
- VX-745
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- EIP Pharma Inc
Lewy Body Dementia
A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
A randomized placebo-controlled trial to evaluate the safety and efficacy of three doses of study drug LY3154207 treated for 12 weeks in participants with mild-to-moderate dementia associated with LBD (PDD or DLB).
- Trial name
- PRESENCE (NCT03305809)
- Testing
- LY3154207
- Where
- 77 sites in United States, Canada and 1 more
- Volunteers
- 344 people
- Sponsor
- Eli Lilly and Company